The ESMO TAT Congress, held in Paris, was the setting for presenting the latest scientific advances in oncology, primarily focused on early phase (phase 1) clinical studies. In this context, Chilean oncologist Carlos Rojas, director of the Bradford Hill Clinical Research Center, presented a multicenter phase 1 study that promises to open new perspectives in cancer treatment. Specifically, through a therapy directed against the KRAS G12C mutation, a genetic alteration present in up to 1 in 4 cancer patients, particularly in lung and colon tumors.